GBT440 Increases Hematocrit and Improves Biventricular Function in Berkeley Sickle Cell Disease Mice

Area of Science:

• Hematology
• Cardiology
• Pharmacology

Background:

• Sickle cell disease (SCD) is an inherited blood disorder characterized by red blood cell sickling and hemolysis due to hemoglobin polymerization.
• Chronic SCD leads to anemia and biventricular cardiac dysfunction.
• GBT440 is an investigational drug designed to inhibit hemoglobin polymerization.

Purpose of the Study:

• To evaluate the therapeutic efficacy of GBT440 in a mouse model of sickle cell disease.
• To assess the impact of GBT440 on hematocrit and biventricular function in SCD mice.

Main Methods:

• Administration of GBT440 to 17-month-old Berkeley SCD mice for three weeks.
• Comparison of hematocrit, left ventricular ejection fraction (LVEF), stroke volume index, and right ventricular function between GBT440-treated and vehicle-treated SCD mice.

Main Results:

• GBT440 treatment effectively resolved chronic anemia in SCD mice.
• Significant improvements were observed in left ventricular ejection fraction (LVEF) and stroke volume index.
• Right ventricular function was notably enhanced following GBT440 administration.

Conclusions:

• GBT440 demonstrates a significant therapeutic effect in an in vivo mouse model of sickle cell disease.
• The findings support GBT440's potential as a treatment for SCD, particularly for cardiac complications.
• Further research into the mechanisms underlying GBT440's cardioprotective effects is warranted.